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 ABSTRACT 
EXPRESSION AND PURIFICATION OF SNAKE ANTIVENOM PEPTIDE IN 
PICHIA PASTORIS 
 
by Israel Juarez Contreras 
It has been shown that a peptide of the first 10-15 N-terminal amino acids of the 
lethal toxin neutralizing factor (LTNF) protein found in opossums (Didelphis spp.) holds 
promise as a low-cost therapy for snake envenomation. To date, the 11-mer has been 
expressed in E. coli and shown to neutralize snake venoms. However, possible endotoxin 
concerns warrant an investigation into other microbial hosts. The methylotrophic yeast, 
Pichia pastoris, shows promise as an alternative host. Active LTNF peptide was 
expressed and purified in P. pastoris. This was accomplished by subcloning a tandem 
repeat of the first 15 N-terminal amino acids of lethal toxin neutralizing factor (LTNF-
15) into the Pichia expression vector, PPIC9K and transforming the yeast via 
electroporation. Expression of LTNF-15 from Pichia was verified by applying a 
fluorescent histidine tag stain onto a SDS-PAGE gel containing supernatant samples of P. 
pastoris clones. Purification of the LTNF-15 peptide was conducted by Ni-NTA 
purification. It was found that expressed LTNF-15 peptide demonstrated neutralizing 
activity in an in vitro assay using azocasein. In addition, it was determined that a protein 
concentration of 70 mg/L of LTNF-15 was attained during the fermentation process. 
Thus, showing promise of Pichia as a viable production host.  
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CHAPTER ONE 
INTRODUCTION 
In the United States, around 99% of the 6,000 yearly cases of snake envenomation are 
from the subfamily Crotalinae which includes pit vipers and rattlesnakes [1]. 
Characteristic symptoms of crotalid envenomation include localized swelling, and tissue 
necrosis. If left untreated, loss of limbs, kidney failure and death can occur. Current 
antivenom treatment comes from a mix of Fab immunoglobulin fragments from blood of 
healthy sheep immunized with snake venom [2]. However, there are reported 
immunological effects and cost to produce is $14 USD per vial [3].  
The cost of antivenom is a significant factor, particularly in developing countries 
where access to treatment is limited or nonexistent. According to the World Health 
Organization (WHO), there are about 5 million annual cases of snake envenomation, of 
which 500,000 cases lead to permanent disability or death [4]. Most of these cases arise 
in developing countries, such as India, where the annual mortality rate due to snake 
envenomation is estimated to be around 46,000 people [5].  
It has been reported that mammals such as Didelphidae (opossum) show resistance to 
snake envenomation [6]. Investigation into opossum serum revealed a variety of proteins 
capable of neutralizing components of snake venom. Several of these proteins exhibit 
similar characteristics, most notable of which the presence of the same five amino acid 
sequence, LKAMD, at the start of the N-terminus [7-9]. Further work conducted by Lipps 
identified a 68 kDa protein called Lethal Toxin Neutralizing Factor (LTNF) in the 
opossum serum. Lipps postulated that LTNF can serve as a universal and alternative 
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treatment for envenomation. Further work on LTNF by Lipps demonstrated that only the 
first 10-15 N-terminal amino acids of LTNF consisting of LKAMDPTPPLWIKTE were 
required for complete neutralization of snake venom activity [10]. Therefore, a synthetic 
peptide consisting of 10-15 amino acids of LTNF could be produced and used as a 
treatment for snake envenomation.  
The production of recombinant proteins in microorganisms has revolutionized the 
field of biotechnology. Previously, large quantities of biological samples of organisms 
were required for the purification of small amounts of protein. The current method now 
involves simply incorporating a gene of interest into a microbe of choice and growing the 
microbe in a bioreactor. This method has produced valuable therapies including insulin, 
anti-malarials, cancer treatments and many others.   
Current research into LTNF recently conducted by Komives confirmed Lipps’ claim 
of synthetic LTNF neutralizing snake venom. In addition, Komives demonstrated the 
ability of recombinant LTNF produced in the gram-negative bacteria, E. coli, to partially 
neutralize snake venom [11]. The inability of the peptide to provide 100% neutralization 
was likely due to the presence of residual contaminants from the purification process, as 
the process had not been optimized. Furthermore, most recombinant LTNF produced in 
E. coli formed inclusion bodies, which are densely packed, denatured protein molecules 
in the form of particles. The process of recombinant protein recovery from inclusion 
bodies is labor intensive and the resulting yields are often low [12]. As a result, it is 
recommended to investigate other production hosts for recombinant LTNF expression.  
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The methylotrophic yeast, Pichia pastoris is a commonly used recombinant 
production host capable of growing to high cell densities and producing gram amounts of 
recombinant protein per liter of culture [13]. Purification of P. pastoris-produced 
recombinant protein is straightforward, as most protein secreted into the growth medium 
is recombinant protein. Purification requires a less labor-intensive process as well as an 
improved yield and recovery when compared to E. coli. In this project, recombinant 
LTNF protein production by P. pastoris was investigated together with purification of the 
peptide resulting in a bioactive peptide.  
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CHAPTER TWO 
LITERATURE REVIEW 
The availability of snake antivenom is a global health issue affecting many regions of 
the world including Sub-Saharan Africa and Southeast Asia [2]. A variety of factors limit 
the availability of snake antivenom in these regions, ranging from the complications 
involved in preparing region-specific antivenom mixtures, to the difficulty of maintaining 
regional production systems [2]. Currently, snake antivenom is produced by injecting a 
non-lethal dose of snake venom into a host animal such as a horse or sheep and 
harvesting the antibodies produced by the animal in response to the venom [2]. 
In the 1990s, Lipps identified and isolated a peptide found in opossum serum called 
LTNF which she erroneously reported to be effective against the venoms of several 
species of snake, including those with lethal neurotoxins [6]. Unfortunately, little 
progress had been made until 2016 when Komives was able to produce a recombinant 
form of the first 11 amino acids of LTNF in E. coli which exhibited neutralizing activity 
[11]. The difficulty of purifying the peptide from inclusion bodies was attributed to a low 
yield and partially purified product that necessitates optimization [11].  However, a team 
in India was able to obtain high yields and purity for the LTNF-11 from the E. coli strain 
[14]. Still, the presence of E. coli endotoxin in biotherapeutics produced in E. coli is a 
motivation to explore the production in other hosts [15]. 
The methylotrophic yeast, Pichia pastoris, is one of the most extensively studied 
yeast species due to its superior ability to produce large quantities of recombinant protein 
and express proteins that could not be produced effectively in other recombinant hosts 
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[13]. Investigation of LTNF expression in Pichia pastoris was carried out in this project. 
This was conducted by transforming Pichia pastoris with a recombinant plasmid, 
PPIC9K, containing a gene to encode a concatenated peptide chain of the LTNF-15 with 
a 6x-His tag. A literature review was conducted to gain a better understanding to the 
characteristics of Pichia pastoris expression system and to examine methods used in 
developing recombinant Pichia strains.  
2.1 The Pichia Expression System 
2.1.1 A Brief History 
Development of the initial protocols for growing P. pastoris on methanol at high cell 
densities was conducted by the Phillips Petroleum Company [14,15]. This was mainly 
investigated as P. pastoris was considered an inexpensive source of animal feed [16].  
However, due to the energy crisis of the 1970s, the cost of methanol was considerably 
high, ending any interest in Pichia for this application [16].  
In the decade that followed, Phillips Petroleum collaborated with the Salk Institute 
Biotechnology/Industrial Associates Inc (SIBIA) to investigate the potential use of P. 
pastoris for recombinant protein expression. Key developments included the isolation of 
the gene and promoter for alcohol oxidase, which allows for methanol induction in many 
of the commercially available vectors [17-18].  Furthermore, the development of 
auxotrophic strains of Pichia allowed for direct selection of recombinant clones and 
provided a greater range of manipulation [19].  Most of these developments have been 
filed in patent literature and common strains and vectors are commercially available 
through Invitrogen [16].  With these developments, P. pastoris is now widely used as a 
 6 
model eukaryote for cell biology research and is a common host for recombinant protein 
production.  
2.1.2 Methanol Utilization 
A unique characteristic of P. pastoris is the ability to utilize methanol as the sole 
carbon source [20]. Indeed, methanol has a bulk cost comparable to glucose now that new 
catalysts have been developed for conversion of natural gas (CH4) to methanol [21].  
Utilization of methanol by P. pastoris is only possible through a methanol utilization 
pathway consisting of several unique enzymes. The first step in this pathway is the 
oxidation of methanol to formaldehyde, resulting in the formation of hydrogen peroxide. 
For this reason, this initial reaction takes place within the peroxisome [22]. In addition, 
the peroxisome contains the three key enzymes responsible for methanol metabolism: 
alcohol oxidase (AOX), catalase, and dihydroxyacetone synthase [22]. After these initial 
reactions, subsequent reactions occur in the cytosol [22]. Although there are two genes 
present in P. pastoris for AOX: AOX1 and AOX2, the AOX1 gene is primarily 
responsible for most alcohol oxidase activity [23]. AOX1 is tightly regulated and induced 
by methanol to high levels [13].  
Three phenotypes of methanol utilization exist in P. pastoris: Mut+, Mut- and MutS. 
The Mut+ phenotype grows on methanol at the same rate as the wild type and requires 
high feeding rates of methanol in fermentations [14]. Although the Mut- phenotype is 
unable to grow on methanol due to the deletion of both AOX genes, it may be required to 
produce certain recombinant proteins due to the low growth rates exhibited by this 
phenotype [22,23]. The MutS phenotype contains a deletion of the AOX1 gene, resulting 
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in a dependence on the AOX2 gene for methanol metabolism. Since the AOX2 gene is 
not expressed at the high levels of AOX1, the growth rates are slower than the Mut+ 
phenotype but may aid in production of certain recombinant proteins [22]. The common 
Pichia phenotypes used for protein production are Mut+ and MutS [24,25].  
2.1.3 Expression Strains 
Most strains utilized in expression experiments share some similarities and 
differences. For example, all P. pastoris expression strains are derivatives of the lab 
strain NRRL-Y 11430 and have a mutation in the histidinol dehydrogenase gene (HIS4). 
This mutation allows for auxotrophic selection of recombinant transformants [26]. Strains 
have been developed based on their ability to utilize methanol through the deletion of the 
AOX genes. There are instances where strains with deleted AOX genes express foreign 
proteins better than wild type strains and have the added benefit of requiring less 
methanol for induction [27-29], reducing the flammability risks involved when large 
amounts of methanol are required.  
The most common strain of P. pastoris is GS115 which contains the wild type AOX 
genes and grows on methanol at the wild type rate (Mut+) [13]. However, recombinant 
protein degradation can occur due to the expression of native proteases in P. pastoris. 
This is especially true in fermentation processes where a high cell density and lysis of 
cells can increase the likelihood of proteases being expressed [13]. Various methods can 
be used to reduce the likelihood of native protease production, including using an 
unbuffered minimal media to create acidic conditions unsuitable for protease production 
or buffering the media to pH 6.0 [30]. However, if media conditions fail to prevent 
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protein degradation, specialized strains, SMD1163, SMD1165, and SMD1168 can be 
utilized [30]. As derivatives of GS115, these strains are produced from deletions to the 
PEP genes present in GS115, which result in the inability to produce proteases [13] and 
may significantly improve the yield of protein [31]. An enzymatic assay can be 
conducted to determine if a protease deficient strain is required [32]. 
2.1.4 Expression Vectors 
Plasmids designed for recombinant protein expression in Pichia share some 
similarities [30]. Most expression vectors contain an AOX1 promoter, followed by a 
multi-cloning site, a region in the plasmid which contains specific DNA sequences that 
allow restriction enzymes to cleave and insert genes [13]. Many vectors contain the HIS4 
gene, allowing for a selectable marker for transformation experiments. Some vectors 
contain the AOX1 3’ flanking sequence that is used in integrating the gene directly into 
the P. pastoris genome [13]. Certain expression vectors include the alpha-factor signal 
sequence from S. cerevisiae as a means of facilitating secretion of recombinant protein 
[33,34]. Some vectors feature drug-resistance genes that can be used to effectively screen 
clones with multiple copies of the vector [30]. 
2.1.5 Genetic Manipulation 
There are several methods for P. pastoris transformation with varying degrees of 
efficiency [35]. Transformation of yeast by the spheroplast method is done by preparing 
an incomplete enzymatic digestion of the cell wall and incorporating foreign DNA into 
the host [36]. The cell wall is then regenerated when embedded in an agar medium [36]. 
Although this method requires several strenuous and complicated steps, it is well studied 
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and has a high transformation efficiency [35].  However, even with these benefits, this 
method is unfavorable due to the complexity of the process.  
Electroporation is another commonly used technique for transformation of yeast cells 
[35]. Due to the electrical pulse cells are subjected to, pores form through the cell 
membrane, allowing foreign DNA to be delivered [35]. The introduction of an osmotic 
support solution and pretreatment of cells with DTT and lithium chloride enables 
successful electroporation [37]. With these improvements, electroporation is on par with 
the spheroplast method regarding transformation efficiency while being extremely user 
friendly [35]. The only drawback to this method is specialized equipment is required 
[35].  
Using either the spheroplast method or electroporation results in the integration of the 
vector into the P. pastoris genome [36]. This occurs through homologous recombination 
between shared sequences by the vector and genome [36]. The resulting transformants 
are extremely stable, even in the absence of selective pressure and can be stored for an 
indefinite period of time in a mixture containing glycerol at -80°C [32].  
Depending on the features of the expression vector, two results may occur during 
homologous recombination [13].  If the expression vector contains an AOX1 3’ sequence, 
the deletion of wild type AOX1 is replaced by the AOX1 3’ sequence of the expression 
vector. This results in the generation of MutS while Mut+ transformants are generated 
from a recombination event at the wildtype HIS4 gene. This second case is rare, and a 
large amount of transformants may be false positive [30]. This occurs in 10-50% of 
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transformants and can increase if transformation is performed through electroporation 
[13]. 
Multiple gene insertion events can occur spontaneously at low frequencies between 1-
10% [13].  Multi-copy P. pastoris colonies are of high interest, as they tend to produce 
large amounts of recombinant protein. Identification of multicopy-containing colonies is 
conducted by subjecting transformants to varying degrees of the antibiotic to which the 
expression vector encodes resistance. [30] This screening process effectively identifies 
multicopy clones and destroys false positive transformants.  
2.1.6 Post-translation Modifications in Pichia 
P. pastoris has the capacity to perform posttranslational modifications such as 
processing signal sequences, folding, disulfide bridge formation and O- and N-linked 
glycosylation. [13] In mammals, O-linked oligosaccharides are composed of a variety of 
sugars, whereas P. pastoris adds O-linked oligosaccharides composed of only mannose 
residues [13]. In addition, there is a small probability of O- glycosylation to proteins that 
are not natively glycosylated [13]. Meanwhile, N-glycosylation in P. pastoris is different 
compared to higher eukaryotes [38] Higher eukaryotes process glycosylation through a 
series of addition and trimming reactions to generate mixtures of different sugars whereas 
in P. pastoris, N-glycosylation can occur in a similar fashion or can process protein with 
additional carbohydrate, known as hyperglycosylation [30]. Hyperglycosylation proses a 
problem for pharmaceutical grade recombinant proteins as mammals may negatively 
react to hyperglycosylation and the half-life of such proteins may be deleteriously 
affected. [13]  
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2.2 Protein Production in P. pastoris 
2.2.1 Nutritional Requirements 
The majority of recombinant protein expression in Pichia is carried out with complex 
media using recipes available from Invitrogen [30]. These serve as an excellent source of 
nutrients for expression in shake flask but have limitations at a large scale [15]. A 
common example of this is the initial concentration of glucose or glycerol used must be 
optimized for biomass production for large scale processes [15]. In addition, common 
nitrogen sources such as yeast extract and peptone often have batch to batch variability 
[15]. Eliminating these sources of nitrogen in favor of ammonium hydroxide is common 
in fermentation processes [15].  
A defined basal medium with a salt solution with vitamin and trace metal 
supplements is a common fermentation media used for large scale Pichia expression 
[39,40]. Along with being a nitrogen source, ammonium hydroxide is used as a means of 
pH control, but the concentration must be optimized. High concentrations of ammonium 
hydroxide can inhibit cell growth, whereas low concentrations aid in increased protein 
production [41]. Supplementing the media with other nitrogen sources such as yeast 
extract and casamino acids aids in protein secretion while inhibiting native secreted 
proteases [30]. Alternatives to the common basal medium have also been shown to 
improve overall protein yield but appear to depend on the particular protein being 
produced [42].  
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2.2.2 Fermentation Control 
As discussed, the primary components of fermentation media are glycerol, methanol, 
biotin, salts, and trace elements. These are relatively inexpensive and ideal for large scale 
processes [15]. Although glucose is a common carbon source in bacterial fermentations, 
it is avoided in Pichia due to the by-product ethanol being a repressor to the AOX 
promoter [43].  
Methanol monitoring in a Pichia fermentation is critical for successful recombinant 
protein production [14]. Methanol concentrations greater than 2% (w/v) in the 
fermentation vessel can be toxic for the cells and low levels of methanol will result in no 
protein expression [14, 33]. Monitoring of methanol using an off-line biochemistry 
analyzer or gas chromatograph is both laborious and expensive [15]. In addition, 
evaporation of methanol can lead to inaccurate data if there is a time lag between 
sampling and obtaining the analysis.  
Online methods are available for methanol detection, such as sensors capable of 
detecting methanol vapor, but are limited to shake flask and small fermentation vessels 
[44]. If there is a lack of instrumentation or methods for determining methanol 
concentration in the culture, constant monitoring of the dissolved oxygen can be utilized 
to determine whether a culture has a methanol concentration that is outside the optimal 
range [13]. Cultures starved of methanol will correspond to an abrupt increase in DO, 
called a DO spike [13]. Methanol is then manually pumped at a low rate until the DO 
concentration stabilizes between the range of 25-40% of saturation [13].  
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Other factors such as pH and temperature also affect expression levels in fermentation 
processes. For example, recombinant protein might be unstable at particular pH values or 
sensitive to certain operating temperatures [45]. This may be due to the small range of 
temperature (25-30°C) and large range of pH conditions (2-8) in which Pichia can 
reasonably grow well [30].  Optimization is critical for the fermentation process and is 
approached mainly through trial and error [15].  
2.3 Comparison to E. coli 
E. coli is the preferred organism used for recombinant protein production due to fast 
growth and protein production rates. Although Pichia has comparatively fast growth 
rates, protein production spans on the order of days [15,30]. A major advantage of Pichia 
is its capacity to perform post-translational modifications similar to mammalian cells 
[30]. Intracellular mechanisms which modify proteins exist in eukaryotic cells but do not 
exist in prokaryotes such as E. coli, limiting the type of proteins that can be expressed 
[46]. However, eukaryotic proteins have successfully been expressed in E. coli although 
some may be produced in an unstable form [47]. 
Protein aggregates within the cell, called inclusion bodies, may result during 
recombinant protein production in E. coli [48].  These large, spherical particles are the 
result of molecular mechanisms failing to repair or remove misfolded or unfolded protein 
and require additional processing to remove from the cell and refold [49]. E. coli 
typically require an optimization in the purification process where the protein becomes 
denatured and refolded [48,49] whereas proteins secreted from Pichia typically require a 
single step to recover the protein from the culture medium [49].  
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2.4 Summary 
Studies on recombinant protein expression in Pichia appear to follow general 
guidelines developed from the Philips Petroleum company which are widely available 
through the Invitrogen website. Pichia have an optimum growth temperature between 
25°C and 30°C with optimum pH around 6. A variety of growth media for Pichia is 
readily available for both shake flask and fermentation scale processes. With standardized 
protocols increasingly becoming available for use, the ease of using Pichia as a host for 
protein expression has become popular. In addition, previous research has shown the 
peptide is active in E. coli indicating there is a possibility that P. pastoris should produce 
an active peptide with potentially higher yield and purity.  
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CHAPTER THREE 
RESEARCH OBJECTIVE 
3.1 Objective 
The research objective of this project is to develop a strain of Pichia that produces a 
concatenated chain of LTNF-15 peptides, and to produce and purify the peptides.  
3.2 Justification 
There are over 5 million cases of snake envenomation, particularly in developing 
countries where the cost of current antivenom treatment is a barrier for adequate 
treatment. In order to provide low-cost antivenom treatment, a bioprocess can be 
developed that is economical compared to conventional antivenom production. 
Recombinant LTNF-11 from E. coli has shown success in neutralizing snake toxins from 
the subfamily Crotalinae. However, contamination issues from E. coli endotoxins remain 
a concern. It would be beneficial to express LTNF-15 from Pichia since recombinant 
peptides are usually secreted into the culture medium along with low levels of native 
protein, yielding a relatively pure product. Purification of the product from the culture 
medium can then be carried out to obtain a pure product without the presence of residual 
contaminants. In addition, Pichia have been shown to express recombinant products at 
high levels, on the order of grams per liter of culture at high cell densities. Production of 
LTNF-15 from Pichia can potentially lead to a low-cost form of antivenom.  
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CHAPTER FOUR 
MATERIALS AND METHODS 
The project was conducted as follows: subcloning the gene into the PPIC9K vector, 
transformation of Pichia strains GS115 and SMD1168 by electroporation, screening the 
resulting transformants for appropriate phenotype, expression of the peptide, purification 
of the peptide from culture media, and then activity testing of the peptide.  
4. 1 Growth Media Preparation 
Growth media was prepared as follows: LB (1% Tryptone, 0.5% Yeast Extract, 1% 
NaCl, with 1.5 % agar for plates), YPD (1% yeast extract, 2% peptone, 2% dextrose, with 
2% agar for plates), RDB (1M sorbitol, 2% dextrose, 1.34% Yeast Nitrogen Base without 
amino acids, 4 x 10-5 % biotin, 0.005% L-glutamic acid, 0.005% L-methionine, 0.005% 
L-lysine, 0.005% L-leucine, 0.005% L-isoleucine, 2% agar), MD (2% dextrose, 1.34% 
Yeast Nitrogen Base without amino acids, 4 x 10-5 % biotin, 1.5% agar), MM (0.5% 
dextrose, 1.34% Yeast Nitrogen Base without amino acids, 4 x 10-5 % biotin, 1.5% agar), 
BMG (100 mM potassium phosphate pH 6.0, 1.34% Yeast Nitrogen Base without amino 
acids, 4 x 10-5 % biotin, 1% glycerol), BMM (100 mM potassium phosphate pH 6.0, 
1.34% Yeast Nitrogen Base without amino acids, 4 x 10-5 % biotin, 0.5% methanol), 
BMGY (100 mM potassium phosphate pH 6.0, 1.34% Yeast Nitrogen Base without 
amino acids, 4 x 10-5 % biotin, 1% glycerol, 1% yeast extract, 2% peptone), BMMY (100 
mM potassium phosphate pH 6.0, 1.34% Yeast Nitrogen Base without amino acids, 4 x 
10-5 % biotin, 0.5% methanol, 1% yeast extract, 2% peptone) 
 
 17 
4.2 Construction of PPIC9K-snk6 vector 
4.2.1 Vector Preparation 
The gene construct was purchased by Eurofins and provided in a pEX-A2 vector. 
Novablue E. coli was transformed with the Eurofins vector by heat shock. Transformed 
cells were grown overnight in LB media containing ampicillin at 37°C, 180RPM. A 
midiprep was performed on the overnight culture using a PureLink HiPure Plasmid 
Midiprep Kit. The isolated pEX-A2 vector containing the gene construct was stored in a  
-20°C freezer until further use.  
The Pichia expression vector, PPIC9K was transformed into Bl21(DE3) E. coli by 
heat shock. Transformed cells were grown overnight in LB media containing ampicillin. 
Midiprep was performed on the overnight culture using a PureLink HiPure Plasmid 
Midiprep Kit. The isolated PPIC9K vector was stored in a -20°C freezer until further use.  
4.2.2 Cloning and Subcloning 
A double digest of isolated pEX-A2 vector at the AVRII and ECORI sites was 
performed according to the protocols provided by New England Biolabs. The linearized 
vector and cut gene construct were run on a 1% agarose gel at 80V for one hour. The 
gene construct was extracted from the gel using the QIAquick Gel Extraction Kit from 
Qiagen and immediately used for ligation into PPIC9K.  
A sequential digest of isolated PPIC9K vector at the ECORI and AVRII sites was 
performed due to the short distance between the ECORI and AVRII cut sites. This short 
distance prevents efficient double digestion of PPIC9K with both enzymes. The isolated 
PPIC9K vector was initially cut at the ECORI site for an overnight duration, as described 
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by New England Biolabs. The following day, the reaction was heat inactivated at 65°C 
for 30 minutes and the cut vector was recovered by ethanol precipitation. After recovery, 
digestion at the AVRII site was performed. The linearized vector was run on a 1% 
agarose gel at 80V for one hour and extracted from the gel using the QIAquick Gel 
Extraction Kit from Qiagen and immediately used for ligation.  
Ligation of the gene construct into the cut PPIC9K vector was performed using the 
Promega LigaFast Rapid DNA ligation kit. The resulting vector, PPIC9K-snk6 was then 
transformed into Novablue cells by heat shock. The cells containing the vector could 
grow on LB media containing ampicillin. Colonies containing the appropriate construct 
were screened by colony PCR using PPIC9K specific primers and grown in LB media 
containing ampicillin overnight. Midiprep was performed on the overnight culture using a 
PureLink HiPure Plasmid Midiprep Kit. Frozen stocks of positive colonies were prepared 
by preparing a 1:1 mixture of overnight culture and 50% glycerol. Frozen stocks were 
stored in a -80°C freezer.  
4.3 Transformation of P. pastoris 
Transformation of P. pastoris strains GS115 and SMD1168 was performed by 
electroporation according to the procedure by Wu and Letchworth [38]. PPIC9K-snk6 
vector was linearized prior to transformation by an overnight restriction digest at the 
BglII site.  
4.4 Screening for MutS Transformants 
Screening of P. pastoris transformants was done according to the Pichia Expression 
Kit protocols established by Invitrogen. Transformants that were identified as MutS, were 
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subjected to a colony PCR using vector specific primers. Positive transformants were 
then grown in YPD at 28°C, 200 RPM overnight and frozen stocks were prepared. 
4.5 Shake Flask Expression of Peptide 
Shake flask expression of the peptide chain was performed according to the Pichia 
Expression Kit protocols established by Invitrogen with some modifications. Single 
colonies were inoculated in 50 mL of BMG or BMGY medium in a 500 mL baffled flask 
at 28°C, 250 RPM. After 16-18 hours of growth, the OD600 was recorded to determine the 
amount of overnight culture required to inoculate 20 mL of BMM or BMMY medium to 
an initial OD600 of 3.0. 1 mL samples of culture were obtained every 24 hours and 
centrifuged at 13,000 RPM at 25°C for 5 minutes. The cell-free supernatant was then 
stored in the freezer at -20°C for analysis. After the 5-day induction period ended as 
specified by the Invitrogen protocol, the remaining culture was centrifuged at 3,000 RPM 
at 25°C for 15 minutes. The corresponding cell-free supernatant was then stored in the 
freezer at -20°C for analysis.  
4.6 Fermentation  
Fermentation was conducted on the P. pastoris transformant that had good expression 
in shake flasks. All solutions were prepared according to Gleeson et al [50].  
4.6.1 PTM Salts Solution 
The composition is listed in Table 1. A 1,000 mL solution was prepared and filter- 
sterilized. The PTM salts solution was stored in room temperature.  
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Table 1.  PTM Salts Solution Composition.  
Chemical  
Cupric sulfate∙5H2O 2 g 
Sodium Iodide 0.08 g 
Manganese sulfate 3 g 
Sodium molybdate∙2H2O 0.2 g 
Boric Acid 0.02 g 
Cobalt Chloride 0.5 g 
Zinc Chloride 7 g 
Ferrous sulfate∙7H2O 22 g 
Sulfuric Acid 5 mL 
Water (to final volume of 1 L) 
 
4.6.2 Biotin Solution 
Twenty-five mg of biotin was dissolved in 0.02 M of KOH. An additional 0.02 M 
KOH was added for a final volume of 100 mL. The solution was then filter-sterilized and 
stored at 4°C for later use.  
4.6.3 Basal Salts Medium  
The composition is listed in Table 2. Once the basal media was prepared, it was 
autoclaved in a 3.5L bioreactor vessel. After autoclaving and letting the media cool, 4 
mL/L of PTM salts and 4 mL/L of biotin solution were aseptically added.  
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Table 2.  Basal Salts Medium Composition  
Chemical  
Phosphoric Acid, 85% 13.3 mL 
Calcium Sulfate∙2H2O 2.3 g 
Potassium Sulfate 14.3 g 
Magnesium Sulfate∙7H2O 11.7 g 
Potassium Hydroxide 3.9 mL 
Glycerol 40 mL 
Water To final volume of 1 liter 
 
4.6.4 Glycerol Feed Solution 
A 50% (v/v) glycerol feed solution was prepared and autoclaved. After cooling, 12 
mL/L of PTM salts and 12 mL/L of biotin were aseptically added.  
4.6.5 Methanol Feed Solutions 
A 50% (v/v) solution of methanol and a 100% solution of methanol were prepared. 
Twelve mL/L PTM salts and 12 mL/L biotin were aseptically added into each solution.  
4.6.6 Preparation of Seed Culture 
The transformant with the best expression was streaked onto a YPD plate from frozen 
stock and left to grow overnight in a 28°C incubator. The following day, a single colony 
from the plate was used to inoculate a 500 mL flask containing 100 mL of BMGY media 
and left to incubate for 24 hours at 250 RPM, 30°C.  
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4.6.7 Bioreactor Cultivation 
The pH in the bioreactor was adjusted to 5.0 with NH4OH and the media was warmed 
with a heating jacket to 28°C. The temperature in the bioreactor was controlled through 
the Applikon ADI 1030 controller connected with both the heating jacket and a 
circulating water bath controlled at 4°C. The seed culture was aseptically added into the 
bioreactor once pH and temperature reached the desired specifications. The initial stir 
speed in the bioreactor was set at 500 RPM and maintained until the dissolved oxygen 
dropped below 30%. At this point, the stir speed was manually adjusted to maintain 
dissolved oxygen above 30%. In addition, an air flow was initiated and manually adjusted 
to maintain the desired dissolved oxygen saturation.   
A glycerol fed-batch phase was initiated using the 50% glycerol solution described 
previously once a sudden and steady rise in the dissolved oxygen level was observed. 
Glycerol was fed at a rate of 500 milligrams per minute and stopped once the optical 
density of the culture was greater than 350.  
Methanol induction was initiated using the 50% methanol solution described 
previously at a rate of 100 milligrams per minute. The 50% methanol solution was fed 
until dissolved oxygen and pH levels stabilized, indicating the cells had adapted to the 
methanol.  
At this point, feeding of the 100% methanol solution described previously was 
initiated at a rate of 55 milligrams per minute for the remainder of the run. Afterwards, 
the fermentation culture was removed from the bioreactor and centrifuged in 250 mL 
flasks at 3,000 g for 30 minutes. Centrifugation was repeated until all biomass was 
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removed, leaving cell-free fermentation broth. The broth was then stored in -80°C until it 
was processed.  
4.7 Analysis of Samples 
Samples of cell-free supernatant from fermentation and shake flask conditions were 
concentrated using Amicon Ultra-15 Centrifugal Filter Units with a molecular weight 
cutoff of 3kDa or 10kDa. The retentate was collected and stored in -80°C for SDS-PAGE 
analysis.  
4.7.1 SDS-PAGE Analysis 
Due to the presence of native Pichia proteins, a 20% SDS-PAGE gel was prepared to 
provide better resolution of proteins less than 50kDa in size. Samples were prepared as 
follows: Fifty microliters of concentrated cell-free supernatant were added to an equal 
volume of 2X SDS-PAGE loading buffer and boiled at 100°C for five minutes. Twenty 
microliters of each sample and a 5-245 kDa protein marker purchased from Gold 
Biotechnology was then loaded onto the gel. Gels were run in a Tris-Glycine buffer at 
80V for 60 minutes and then at 120V for 90 minutes. After electrophoresis, gels were 
washed in DI water and left overnight in Coomassie colloidal blue stain. Gels were then 
subjected to three DI water washes for visualization of bands. A duplicate electrophoresis 
run was prepared for each set of samples analyzed and stained in Pierce 6xHis Protein 
Tag Stain according to the manufacture’s protocols. Since there is a 6xHis tag 
downstream from the polypeptide sequence, the band corresponding to the peptide will 
fluoresce under UV light after application of the stain.  
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4.8 Purification of Peptide 
Immobilized metal affinity chromatography of cell-free culture supernatant as 
described by Komives et al. was used to purify the LTNF-15 peptide with some 
modifications [11].  
A gravity column was packed with 5 mL of Ni-NTA resin. The column was 
equilibrated with a buffer consisting of 300 mM NaCl and 20 mM of sodium phosphate 
at a pH of 8.0. Afterwards, the resin was transferred into a conical tube containing cell 
free culture broth and allowed to incubate in an orbital shaker overnight at 4°C. The next 
day, the mixture of culture broth and resin was drained by gravity into a column and 
washed with buffer consisting of 300 mM NaCl, 20 mM Sodium Phosphate, and 10 mM 
imidazole pH 8.0. After washing, the resin was equilibrated in 100 mM Ammonium 
bicarbonate buffer and transferred into a conical tube. The resin was then incubated 
overnight with 200 micrograms of endoproteinase Glu-C at 4°C on an orbital shaker. The 
following day, the resin was drained by gravity into a column and washed with 5 column 
volumes of 100 mM ammonium bicarbonate. The flow-through was collected and 
immediately concentrated using a 10,000 MWCO ultrafiltration membrane. The resulting 
permeate was then collected and concentrated using a 1,000 MWCO ultrafiltration 
membrane. The resulting retentate was then polished using a 3,000 MWCO ultrafiltration 
membrane in which the resulting permeate was collected and frozen at -80°C in a freeze-
drying flask overnight. The following day, the sample was then lyophilized using a 
Labconco FreezeZone Benchtop Freeze Dryer for 24 hours. The resulting powder was 
collected and stored at -30°C for analysis.  
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4.9 Azocasein Assay  
An azocasein assay was conducted according to the protocol available from the 
manufacture with some modifications [51]. Solutions of 1% (w/v) azocasein, 1% (w/v) of 
lyophilized C. atrox venom, and 4% (w/v) of LTNF-15 peptide in 20 mM of Tris-HCl 
were prepared. Venom:peptide ratios of 1:1, 1:10 and 1:30 were prepared using 20mM 
Tris-HCl as a diluent. A 60 ug/mL concentration of C. atrox venom with 0.2% azocasein 
was prepared as a control. All reactions and controls were prepared in triplicate. 
Reactions were incubated at 37°C for 5, 15, and 30 minutes and stopped by addition of 
5% (w/v) trichloroacetic acid (TCA). Samples were centrifuged for 10 min at 3,000 g. 
Equal volumes of supernatant and 0.5 M NaOH were mixed and analyzed in a plate 
reader (BioTEK ELX808) at 450 nm. 
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CHAPTER FIVE 
RESULTS AND DISCUSSION 
5.1 Plasmid Construction 
PPIC9K-snk6 plasmid was constructed as described previously and transformed into 
Novablue cells using a standard heat shock protocol. The use of a concatemer of peptides 
is preferable to a single peptide because the resulting size of the peptide concatemer 
facilitates the purification process.  Endoproteinase Glu-C cleaves only on the C end of 
glutamic acid when an acetate buffer is used for the cleavage step.  The cells were plated 
on LB plates containing ampicillin to select for transformants and incubated overnight at 
37°C. The next, day several colonies were selected for colony PCR to identify positive 
transformants. The PCR products were loaded onto a 1% agarose gel for electrophoresis 
as seen in Figure 1. Of the eight colonies that were selected, only two had the expected 
PCR product size of 487 bp whereas the remaining colonies had larger than expected 
PCR products. This can be attributed to a non-ideal vector:insert ratio in the ligation step, 
which resulted in concatemer formation [53].  
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Figure 1. Agarose gel electrophoresis of PPIC9K-snk6 E. coli transformants. Lane 1 
contains the molecular marker. Lanes 2 and 3 contain the appropriately sized PCR 
product whereas lanes 4-9 contain concatemers.  
 
5.2 P. pastoris Transformation 
Immediately after electroporation, Pichia transformants were plated on auxotrophic 
plates lacking histidine. Transformants that have incorporated the PPIC9K-snk6 plasmid 
grew on the plates due to their ability to synthesize histidine whereas wild-type lack this 
ability and therefore failed to grow [26].   
Transformants were screened and identified for the desired MutS phenotype. Colonies 
from the auxotrophic selection plates were patched onto minimal methanol and minimal 
dextrose plates as described previously. Colonies that exhibited the MutS phenotype grew 
well on minimal dextrose medium but grew slowly on the minimal methanol plate. This 
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is due to the wild-type AOX1 gene being removed from the genome during plasmid 
integration via homologous recombination [22].  
Clones that were identified as MutS phenotype from the minimal methanol plates 
were subjected to colony PCR to verify MutS phenotype. In Figure 2, MutS colonies were 
observed to have a PCR product size of around 500 bp. This is to be expected, as the 
primers used were the alpha-Factor and 3’ AOX1 primers, which would yield a product 
size of 188 bp without a gene construct [33]. The LTNF-15 gene construct is 
approximately 292 bp, yielding a PCR product of 487 bp. In addition, MutS phenotype 
yield a single band if using an AOX1 primer whereas Mut+ phenotypes would yield two 
unique bands: wild-type AOX1 and the AOX1 fragment from the PPIC9K plasmid [33].  
 
 
Figure 2. Agarose gel electrophoresis of PPIC9K-snk6 Pichia transformants. Lane 1 
contains the molecular marker. Lane 3 contains a PPIC9K control. Lanes 2, 4-8, are 
colonies that have been verified to be MutS by PCR by patching onto minimal methanol 
plates.  
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5.3 Shake Flask Expression 
After induction, cell-free broth was concentrated as described previously and loaded 
onto a 20% SDS-PAGE gel. Prior to Coomassie blue staining, the gel was stained with 
Pierce His-stain according to the manufacturer’s protocol and observed under UV light as 
seen in Figure 3. Since the LNTF-15 peptide chain contains a 6xHis tag, the bands 
fluorescence under UV light, verifying that the peptide chain is indeed expressed.  
 
 
Figure 3. His-tag stained SDS-PAGE gel of Pichia culture supernatants. Lane 1 the 
protein maker. Lanes 2-7 are Pichia clones, each exhibiting different levels of LTNF-15 
expression.  
 
After application of the 6xHis stain, the gel was then washed and subjected to an 
overnight staining of Coomassie blue seen in Figure 4. Various native secreted Pichia 
proteins are also present in the supernatant.  
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Figure 4. Coomassie blue stained SDS-PAGE gel of Pichia culture supernatants. Lane 1 
the protein maker. Lanes 2-7 are Pichia clones, each exhibiting different levels of LTNF-
15 expression.  
 
5.4 Fermentation 
The transformant with the best expression in shake flasks was selected for 
fermentation. Induction was carried out over a duration of 5 days.  
5.4.1 Growth Rate Curve 
A growth rate curve was constructed by measuring OD600 over time. As seen in 
Figure 5, the exponential phase occurs during the glycerol batch and fed-batch phases. 
Once methanol induction occurs, the cells are in stationary phase. This is to be expected 
due to the MutS phenotype lacking wild type AOX1 and therefore fail to metabolize 
methanol adequately for cell growth in comparison to Mut+ [33].  
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Figure 5.  Growth curve of Pichia fermentation.  
5.4.2 Protein Production 
SDS-PAGE was performed on samples collected at various time points during the 
methanol induction phase of the run. As seen in Figure 6 and Figure 7, a band of around 
11 kDA is present, indicating the peptide is indeed expressed. Protein production was 
quantified by densiometric analysis using ImageJ and lysozyme as a standard. Figure 8 
shows protein production plateaus around 120 hours or 50 hours post induction.  
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Figure 6. SDS-PAGE analysis of fermentation samples from 70-120 hours. Lane 1 
contains the protein marker. Lanes 2-5 contain lysozyme standards used for densiometric 
analysis. Lanes 6-15 contain supernatant samples collected from the 70th hour of 
fermentation through the 120th hour.  
 
 
 
Figure 7. SDS-PAGE analysis of fermentation samples from 120-170 hours. Lane 1 
contains the protein marker. Lanes 2-11 contain supernatant samples collected from the 
120th hour of fermentation through the 170th hour. Lanes 12-15 contain lysozyme 
standards used for densiometric analysis. 
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Figure 8.  LTNF-15 production in Pichia fermentation.   
5.5 Purification 
Flow through from the binding and wash steps were collected for SDS-PAGE 
analysis. Elution of LTNF-15 peptide resulted using saline buffer as described previously 
with the addition of 500 mM imidazole. As seen in Figure 9, flow through from the 
binding step (lane 2) contains LTNF-15 peptide, indicating that the resin exceeded its 
binding capacity. Flow through from the washing step (lane 3) contains trace 
contaminating proteins and LTNF-15 peptide. The wash buffer contains 10 mM 
imidazole, thus contaminating proteins do not require a high imidazole concentration to 
be washed from the resin. As described in Section 4.8, following washing, the resin is 
equilibrated with 100 mM ammonium bicarbonate and left to incubate with 
endoproteinase Glu-C before recovering the LTNF-15 peptide and performing a series of 
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ultrafiltration steps. However, to ensure LTNF-15 peptide was binding to the Ni-NTA 
resin, an imidazole elution step was conducted instead. Lane 4 shows the resulting eluent, 
showing a pure LTNF-15 band. Although there is a single band present in Figure 9, it is 
plausible to conclude that there are contaminating proteins left, as the range of detection 
for colloidal Coomassie blue staining is less than 250 ug [53]. 
 
Figure 9. SDS-PAGE of LTNF-15 purification using Ni-NTA resin. Lane 1 contains the 
protein marker. Lane 2 is the flow through from the binding step. Lane 3 is the flow 
through from the wash step. Lane 4 is the eluted LTNF-15 peptide using imidazole. 
 
5.6 Azocasein Assay 
Slight inhibition of C. atrox venom was seen with LTNF-15 peptide at a venom 
peptide ratio of 1:1. Inhibition of about 20% and 30% was observed with LTNF-15 
peptide at venom peptide ratios of 10:1 and 30:1 respectively.  By comparison, azocasein 
assay data in Figure 11 for LTNF-11 peptide behaves in a similar fashion. This suggests 
that LTNF peptides do not neutralize all the proteases present in C. atrox venom.  
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The azocasein assay is suitable for evaluating LTNF activity against C. atrox venom 
due to the venom containing metalloproteinases. Azocasein is a protease substrate which 
releases azo dye into the solution when the casein is degraded by a protease [55]. This 
yields TCA-soluble azopeptides that can be detected at an absorbance of 450 nm [55].  
 
 
Figure 10. Partial neutralization of C. atrox venom proteolytic activity by LTNF-15 
peptide 
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Figure 11. Partial neutralization of C. atrox venom proteolytic activity by LTNF-11 
peptide. 
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CHAPTER SIX 
CONCLUSION AND FUTURE WORK 
6.1 Conclusion 
LTNF-15 production by Pichia Pastoris was achieved by transforming wild type 
GS115 with the constructed PPIC9K-S6 by electroporation. LTNF-15 was successfully 
expressed in P. pastoris transformants in shake flasks and in a bioreactor. Active LTNF-
15 peptide was confirmed by azocasein assay; however the peptide was unable to 
properly dissolve in solution while conducting in vivo assays. This can possibly be due to 
contaminating material that remained post purification.   
6.2 Future Work 
Future work will consist of expressing LTNF peptide in P. pastoris without the 
additional hydrophilic residues. This will stabilize the LTNF peptide and therefore be 
soluble in solution. Currently, the shorter LTNF peptide has been subcloned into the 
PPIC9K expression vector, and successfully expressed in shake flasks. Further work will 
be conducted on bioreactor cultivation and purification strategies, before assessing 
activity in azocasein and mice assays.  
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